Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in Leishmania tarentolae
Identifieur interne : 001D90 ( PascalFrancis/Curation ); précédent : 001D89; suivant : 001D91Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in Leishmania tarentolae
Auteurs : Corinne Pion [France] ; Virginie Courtois [France] ; Stéphanie Husson [France] ; Marie-Clotilde Bernard [France] ; Marie-Claire Nicolai [France] ; Philippe Talaga [France] ; Emanuelle Trannoy [France] ; Catherine Moste [France] ; Régis Sodoyer [France] ; Isabelle Legastelois [France]Source :
- Vaccine [ 0264-410X ] ; 2014.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The membrane displayed antigen haemagglutinin (HA) from several influenza strains were expressed in the Leishmania tarentolae system. This non-conventional expression system based on a parasite of lizards, can be readily propagated to high cell density (>108 cells/mL) in a simple incubator at 26°C. The genes encoding HA proteins were cloned from six influenza strains, among these being a 2009 A/H1N1 pandemic strain from swine origin, namely A/California/07/09(H1N1). Soluble HA proteins were secreted into the cell culture medium and were easily and successfully purified via a His-Tag domain fused to the proteins. The overall process could be conducted in less than 3 months and resulted in a yield of approximately 1.5-5 mg of HA per liter of biofermenter culture after purification. The recombinant HA proteins expressed by L. tarentolae were characterized by dynamic light scattering and were observed to be mostly monomeric. The L. tarentolae recombinant HA proteins were immunogenic in mice at a dose of 10 μg when administered twice with an oil-in-water emulsion-based adjuvant. These results suggest that the L. tarentolae expression system may be an alternative to the current egg-based vaccine production.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000029
Links to Exploration step
Pascal:14-0250685Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in Leishmania tarentolae</title><author><name sortKey="Pion, Corinne" sort="Pion, Corinne" uniqKey="Pion C" first="Corinne" last="Pion">Corinne Pion</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Courtois, Virginie" sort="Courtois, Virginie" uniqKey="Courtois V" first="Virginie" last="Courtois">Virginie Courtois</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Husson, Stephanie" sort="Husson, Stephanie" uniqKey="Husson S" first="Stéphanie" last="Husson">Stéphanie Husson</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Bernard, Marie Clotilde" sort="Bernard, Marie Clotilde" uniqKey="Bernard M" first="Marie-Clotilde" last="Bernard">Marie-Clotilde Bernard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Nicolai, Marie Claire" sort="Nicolai, Marie Claire" uniqKey="Nicolai M" first="Marie-Claire" last="Nicolai">Marie-Claire Nicolai</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Talaga, Philippe" sort="Talaga, Philippe" uniqKey="Talaga P" first="Philippe" last="Talaga">Philippe Talaga</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Trannoy, Emanuelle" sort="Trannoy, Emanuelle" uniqKey="Trannoy E" first="Emanuelle" last="Trannoy">Emanuelle Trannoy</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Moste, Catherine" sort="Moste, Catherine" uniqKey="Moste C" first="Catherine" last="Moste">Catherine Moste</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Sodoyer, Regis" sort="Sodoyer, Regis" uniqKey="Sodoyer R" first="Régis" last="Sodoyer">Régis Sodoyer</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Technology Research Institute Bioaster, 317 Avenue Jean-Jaurès</s1><s2>69007 Lyon</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Legastelois, Isabelle" sort="Legastelois, Isabelle" uniqKey="Legastelois I" first="Isabelle" last="Legastelois">Isabelle Legastelois</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0250685</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0250685 INIST</idno><idno type="RBID">Pascal:14-0250685</idno><idno type="wicri:Area/PascalFrancis/Corpus">000029</idno><idno type="wicri:Area/PascalFrancis/Curation">001D90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in Leishmania tarentolae</title><author><name sortKey="Pion, Corinne" sort="Pion, Corinne" uniqKey="Pion C" first="Corinne" last="Pion">Corinne Pion</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Courtois, Virginie" sort="Courtois, Virginie" uniqKey="Courtois V" first="Virginie" last="Courtois">Virginie Courtois</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Husson, Stephanie" sort="Husson, Stephanie" uniqKey="Husson S" first="Stéphanie" last="Husson">Stéphanie Husson</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Bernard, Marie Clotilde" sort="Bernard, Marie Clotilde" uniqKey="Bernard M" first="Marie-Clotilde" last="Bernard">Marie-Clotilde Bernard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Nicolai, Marie Claire" sort="Nicolai, Marie Claire" uniqKey="Nicolai M" first="Marie-Claire" last="Nicolai">Marie-Claire Nicolai</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Talaga, Philippe" sort="Talaga, Philippe" uniqKey="Talaga P" first="Philippe" last="Talaga">Philippe Talaga</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Trannoy, Emanuelle" sort="Trannoy, Emanuelle" uniqKey="Trannoy E" first="Emanuelle" last="Trannoy">Emanuelle Trannoy</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Moste, Catherine" sort="Moste, Catherine" uniqKey="Moste C" first="Catherine" last="Moste">Catherine Moste</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Sodoyer, Regis" sort="Sodoyer, Regis" uniqKey="Sodoyer R" first="Régis" last="Sodoyer">Régis Sodoyer</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Technology Research Institute Bioaster, 317 Avenue Jean-Jaurès</s1><s2>69007 Lyon</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Legastelois, Isabelle" sort="Legastelois, Isabelle" uniqKey="Legastelois I" first="Isabelle" last="Legastelois">Isabelle Legastelois</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>France</country></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Hemagglutinin</term><term>Immunogenicity</term><term>Influenza</term><term>Leishmania tarentolae</term><term>Mouse</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Souris</term><term>Leishmania tarentolae</term><term>Immunogénicité</term><term>Hémagglutinine</term><term>Grippe</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The membrane displayed antigen haemagglutinin (HA) from several influenza strains were expressed in the Leishmania tarentolae system. This non-conventional expression system based on a parasite of lizards, can be readily propagated to high cell density (>10<sup>8</sup> cells/mL) in a simple incubator at 26°C. The genes encoding HA proteins were cloned from six influenza strains, among these being a 2009 A/H1N1 pandemic strain from swine origin, namely A/California/07/09(H1N1). Soluble HA proteins were secreted into the cell culture medium and were easily and successfully purified via a His-Tag domain fused to the proteins. The overall process could be conducted in less than 3 months and resulted in a yield of approximately 1.5-5 mg of HA per liter of biofermenter culture after purification. The recombinant HA proteins expressed by L. tarentolae were characterized by dynamic light scattering and were observed to be mostly monomeric. The L. tarentolae recombinant HA proteins were immunogenic in mice at a dose of 10 μg when administered twice with an oil-in-water emulsion-based adjuvant. These results suggest that the L. tarentolae expression system may be an alternative to the current egg-based vaccine production.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0></fA01><fA02 i1="01"><s0>VACCDE</s0></fA02><fA03 i2="1"><s0>Vaccine</s0></fA03><fA05><s2>32</s2></fA05><fA06><s2>43</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in Leishmania tarentolae</s1></fA08><fA11 i1="01" i2="1"><s1>PION (Corinne)</s1></fA11><fA11 i1="02" i2="1"><s1>COURTOIS (Virginie)</s1></fA11><fA11 i1="03" i2="1"><s1>HUSSON (Stéphanie)</s1></fA11><fA11 i1="04" i2="1"><s1>BERNARD (Marie-Clotilde)</s1></fA11><fA11 i1="05" i2="1"><s1>NICOLAI (Marie-Claire)</s1></fA11><fA11 i1="06" i2="1"><s1>TALAGA (Philippe)</s1></fA11><fA11 i1="07" i2="1"><s1>TRANNOY (Emanuelle)</s1></fA11><fA11 i1="08" i2="1"><s1>MOSTE (Catherine)</s1></fA11><fA11 i1="09" i2="1"><s1>SODOYER (Régis)</s1></fA11><fA11 i1="10" i2="1"><s1>LEGASTELOIS (Isabelle)</s1></fA11><fA14 i1="01"><s1>Department of Research and Development, Sanofi Pasteur, 1541 Avenue Marcel Mérieux</s1><s2>69280 Marcy L'Etoile</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="02"><s1>Technology Research Institute Bioaster, 317 Avenue Jean-Jaurès</s1><s2>69007 Lyon</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA20><s1>5570-5576</s1></fA20><fA21><s1>2014</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20289</s2><s5>354000508274280080</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>40 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0250685</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Vaccine</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>The membrane displayed antigen haemagglutinin (HA) from several influenza strains were expressed in the Leishmania tarentolae system. This non-conventional expression system based on a parasite of lizards, can be readily propagated to high cell density (>10<sup>8</sup> cells/mL) in a simple incubator at 26°C. The genes encoding HA proteins were cloned from six influenza strains, among these being a 2009 A/H1N1 pandemic strain from swine origin, namely A/California/07/09(H1N1). Soluble HA proteins were secreted into the cell culture medium and were easily and successfully purified via a His-Tag domain fused to the proteins. The overall process could be conducted in less than 3 months and resulted in a yield of approximately 1.5-5 mg of HA per liter of biofermenter culture after purification. The recombinant HA proteins expressed by L. tarentolae were characterized by dynamic light scattering and were observed to be mostly monomeric. The L. tarentolae recombinant HA proteins were immunogenic in mice at a dose of 10 μg when administered twice with an oil-in-water emulsion-based adjuvant. These results suggest that the L. tarentolae expression system may be an alternative to the current egg-based vaccine production.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05F04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Souris</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Mouse</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Ratón</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Leishmania tarentolae</s0><s2>NS</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Leishmania tarentolae</s0><s2>NS</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Leishmania tarentolae</s0><s2>NS</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Immunogénicité</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Immunogenicity</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Inmunogenicidad</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Hémagglutinine</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Hemagglutinin</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Hemoaglutinina</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Grippe</s0><s5>14</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Influenza</s0><s5>14</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Gripe</s0><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Kinetoplastida</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Kinetoplastida</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Kinetoplastida</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Protozoa</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Protozoa</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Protozoa</s0><s2>NS</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Infección</s0></fC07><fN21><s1>307</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001D90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:14-0250685
|texte= Characterization and immunogenicity in mice of recombinant influenza haemagglutinins produced in Leishmania tarentolae
}}
| This area was generated with Dilib version V0.6.34. |  |